ASPC-VirtualSummitLogo_WebBanner_Enduring-2200

Live Summit Overview

The ASPC 2021 Summit on CVD Prevention was held virtually from July 23-25, 2021. Attendees of the live program can claim up to 15.5 CE/MOC credits. Please utilize the link below to claim your credits. Registered attendees of the Live Congress automatically have access to the enduring (on-demand) program. If would like to access the enduring content, please log in to your account at www.aspcvirtualsummit.org.If you attended the live Virtual Summit, you can claim credit until August 31, 2021.

Enduring OnDemand Program 

The ASPC online scientific sessions are now available OnDemand/Enduring, and emphasize inclusiveness and the care of one and all at risk for cardiovascular disease. The program provides cutting-edge lectures, lively debates, and practical applications. We explore the broad spectrum of preventive cardiology led by world-renowned experts in the field. It covers topics such as Emerging Therapies for Lipid Management, CAC vs. Biomarkers, Chest Pain and Imaging, Prevention of Heart Failure, Atrial Fibrillation, PAD Evaluation, Treatment, and Management, Practical Application of New Prevention Therapies, CVD Prevention in Special Populations, and more.

The Enduring/OnDemand Program offers up to 11.5 CE/MOC credits. The sessions are available to watch from August 6 - December 6, 2021. Credits must be claimed by December 6th.

Target Audience

This activity is designed for an audience of physicians, physician assistants, nurses, pharmacists, dieticians, research scientists and other healthcare professionals.

Learning Objectives

Upon completion of the educational activity, participants should be able to:

Session 1: Opening Session

  • Identify the evolution on Primary and Secondary Prevention of CVD and apply the current recommendations into practice.
  • Critically evaluate emerging lipid therapies and assess their ASCVD risk reduction while implementing this knowledge into clinical practice.
  • Critically evaluate the literature involving CVD risk in CKD and DM patients in an effort to implement this knowledge into clinical practice.
  • Critically compare the literature involving biomarkers versus CAC testing in ASCVD prevention and implement this knowledge into clinical practice.

Session 2:  Early Career Award Lectures

  • Review the latest research in the prevention field and apply to your clinical practice.

Session 3:  Debate:  CAC vs. BioMarkers

  • Critically compare the literature involving biomarkers versus CAC testing in ASCVD prevention and implement this knowledge into clinical practice.

Session 4:  Ischemic Heart Disease

  • Assess and evaluate current ACS treatment strategies in patients with COVID-19 and implement into daily management.
  • Evaluate the different types of Ischemic Heart Disease and determine the best evaluation and treatment to apply in clinical practice.
  • Critically evaluate the latest literature to determine the pretest probability (PTP) of coronary artery disease (CAD) in symptomatic patients and how to proceed with test selection and implement this knowledge into clinical practice.

Session 5:  The Great Diet Debate

  • Critically evaluate the literature involving diets to reduce cardiovascular risk and implement this knowledge into clinical practice.

Session 6:  Nanette Wenger Lecture

  • Critically Evaluate the rational and results of the VITAL trial and determine which patients would benefit from supplementation.

Session 7:  Honorary Fellowship Lecture:

  • Discuss the contribution of adverse Social Determinants of Health on CV outcomes.
  • Demonstrate the pernicious influence of structural barriers that impede equitable health.
  • Explore proactive steps to narrow disparities and achieve health equity.

Session 8: Working in Prevention

  • Critically evaluate the literature involving lifestyle modifications to prevent heart failure and implement this knowledge into clinical practice.
  • Analyze strategies to prevent atrial fibrillation and implement this knowledge into clinical practice.
  • Evaluate the medical and lifestyle management of PAD that incorporate therapies to improve functional outcomes, reduce adverse cardiovascular, and limb events.

Session 9:  Practical Applications of New Prevention Therapies

  • Implement strategies to improve care, prevent heart disease, and incorporate this knowledge into clinical practice.

Session 10:  Practical Strategies in Practice

  • Critically evaluate best practices in telemedicine, including proper billing, and implement this knowledge into clinical practice.

Session 11:  Joseph Stokes III, MD, Award Lecture

  • Describe how epidemiologic studies have led to key features of the prevention guideline.

Session 12:  Special Populations

  • Critically evaluate the literature involving transgender patients, CVD, and hormone replacement therapy and implementing this knowledge into clinical practice.
  • Discuss current strategies to prevent heart disease, stroke, and diabetes through proper diet and accessibility and implement this knowledge into clinical practice.
  • Evaluate the literature involving the unmet needs in the use of statins and aspirin in PLWHIV and review the incompleteness of the current guideline to implement any prevention knowledge into clinical practice.
  • Evaluate the clinical data involving Cardiovascular risk among individuals of South Asian Ancestry.

Criteria for Success

To obtain a certificate of completion, a score of 70% or better on the post-test is required. Please proceed with the activity until you have successfully completed this program, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your certificate.  You must participate in the entire activity to receive (session) credit. If you have questions about this activity, please contact AKH Inc. at lritley@akhcme.com.

Credit provided by AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology.

In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and The American Society for Preventive Cardiology. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physicians
AKH Inc., Advancing Knowledge in Healthcare designates this live activity for a maximum of 11.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of the CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.5 medical knowledge MOC points and 0 patient safety MOC credit in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

AAPA Credit Designation Statement
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 11.5 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.

 

Commercial Support
Full notification of commercial support will be provided in the final course syllabus.

 

ASPC 2021 Virtual Summit Satellite Symposia

Now available OnDemand at www.aspcvirtualsummit.org

Saving the Hearts of Women Through Prevention 

During this satellite symposia, expert faculty address CVD risk factors, tools, and guidelines to screen females for CV risk. They  also examine recent advances in lifestyle modifications, primary and secondary prevention, and considerations for women with type 2 diabetes to improve health outcomes and reduce CVD mortality.

Learning Objectives:

  • Summarize gender-specific factors that influence cardiovascular (CV) risk in women.
  • Evaluate appropriate tools and guidelines to screen females for CV risk.
  • Examine the latest evidence regarding the use of non-statin therapies to reduce LDL-C or triglycerides in patients with ASCVD with or without risk enhancers.
  • Review the latest clinical evidence regarding the impact of newer anti-diabetes medications on CV risk.

Co-Chairs:

Martha Gulati, MD, MS, FACC, FAHA, FASPC
Division Chief of Cardiology, University of Arizona-Phoenix—Professor of Medicine
Editor-in Chief of CardioSmart for the American College of Cardiology
Phoenix, AZ

Erin D. Michos, MD, MHS, FACC, FAHA, FASE, FASPC
Associate Professor of Medicine & Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Cardiovascular Disease
Johns Hopkins University School of Medicine
Baltimore, MD

Faculty:

Alison L. Bailey, MD, FASPC, FACC
Chief, Cardiology
Centennial Heart at Parkridge
Co-director of the Center for Heart, Lung and Vascular Health at Parkridge
Parkridge Health System
Physician Director, Cardiovascular Disease
HCA Healthcare
Chattanooga, TN

Pam R. Taub, MD, FACC, FASPC
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Professor of Medicine
UC San Diego Health System
Division of Cardiovascular Medicine
La Jolla, CA

Utilizing Real-World Evidence to Optimize Outcomes in Type 2 Diabetes – Reducing Cardiovascular Disease & CV Risk

Now Available OnDemand

This symposium highlights and provides a meticulous overview of real-world evidence collected for optimizing outcomes in patients with type 2 diabetes, specifically aiming to reduce cardiovascular events, as well as patient hospitalizations, considering clinicians must know the best practices to keep their T2D patients healthy and out of the ER during these trying times.

Learning Objectives:

After Completion of this educational activity, attendees will be able to:

  1. Examine current treatment guidelines for patients with T2D for effective management of cardiovascular risk
  2. Evaluate the real-world evidence for reducing CV events and hospitalizations to improve outcomes for patients with T2D
  3. Apply emerging clinical data on issues in management and prevention of CVD in patients with T2D

Faculty:

Peter P. Toth, MD, PhD, FCCP, FASPC, FAHA (Program Chair)
President, American Society for Preventive Cardiology
Director of Preventive Cardiology
Sterling, Illinois

Alison L. Bailey, MD, FASPC
Chief, Cardiology
Centennial Heart at Parkridge
Chattanooga, TN

Harold E. Bays, MD, FOMA, FTOS, FACC, FASPC
Medical Director and President
Louisville Metabolic and Atherosclerosis Research Center
Louisville, KY

Pam R. Taub, MD, FACC, FASPC
Director of Step Family Foundation Cardiovascular Rehabilitation and Wellness Center
Associate Professor of Medicine
La Jolla, CA

This Education Activity is sponsored by unrestricted educational grants for Boehringer Ingelheim Pharmaceuticals and Lilly USA, LLC.

 

2021 Exhibit Booth Sponsors

Cardiology News